# Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Source: https://onco.cc/trials/nct04268706/  
OnCo record `nct04268706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fludarabine, Bendamustine in hodgkin lymphoma, run by Tessa Therapeutics, active and no longer recruiting.

## Summary

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) is a phase 2 interventional study registered as NCT04268706 by Tessa Therapeutics, with 97 participants planned, started 2021-02-01 and due to reach its primary completion in 2025-05. Interventions recorded: CD30.CAR-T, Fludarabine, Bendamustine. Conditions listed: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04268706
- Phase: 2
- Setting: A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Sponsor: Tessa Therapeutics
- Enrolled: 97

## Sources

- ClinicalTrials.gov NCT04268706: https://clinicaltrials.gov/study/NCT04268706

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct04268706.json